BioLineRx (NASDAQ: BLRX) reported Q2 EPS of $0.00, $0.14 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.39 million versus the consensus estimate of $2.94 million.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.